Related references
Note: Only part of the references are listed.Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
Amit Khatri et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Yinuo Pang et al.
CLINICAL PHARMACOKINETICS (2020)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials
Ahmed A. Suleiman et al.
CLINICAL PHARMACOKINETICS (2019)
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Subrata Ghosh et al.
DRUG SAFETY (2019)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich et al.
LANCET (2019)
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease
B. G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study
Siew C. Ng et al.
GASTROENTEROLOGY (2013)